Last reviewed · How we verify
NCT06891092
Vivinex Impress XY1-EM vs RayOne EMV
NA trial testing RayOne EMV in Cataract in 100 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | Medical University of Bialystok |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 January 2026 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 June 2028 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- RayOne EMV
- Vivinex Impress
Conditions studied
- Cataract — all drugs for Cataract →
Sponsor
Medical University of Bialystok
Who can join
Adults 21 to 80, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Comparison of the outcomes of bilateral implantation of extended depth of vision (EDOF) intraocular lenses (IOLs): the Rayone EMV and the Vivinex Impress XY1-EM in patients with cataract
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06891092
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cataract
Currently open trials in the same condition.
- NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
- NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
- NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
- NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
- NCT07176416 — Effective Phaco Time and Endothelial Cell Loss When Using Veritas · recruiting
Other Medical University of Bialystok trials
Trials by the same sponsor.
- NCT07496957 — Preserflo MicroShunt Versus Trabeculectomy · NA · recruiting
- NCT07325552 — iStent Inject Versus Goniotomy With Kahook Dual Blade in Glauocma Treatment · NA · recruiting
- NCT07529145 — Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment · recruiting
- NCT06855979 — The Impact of Dietary Intervention on Oxidative/antioxidant Markers and Gut Microbiota in Athletes · NA · completed
- NCT07324252 — Small RNA Profiling in EBC in Athletes · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06891092 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Bialystok
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06891092.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing